{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:14:46Z","timestamp":1781334886222,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["JP21K09758"],"award-info":[{"award-number":["JP21K09758"]}]},{"name":"JSPS KAKENHI","award":["JP23K09057"],"award-info":[{"award-number":["JP23K09057"]}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the effects of subthreshold micropulse laser (SML) in addition to anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were systematically searched for studies that compared anti-VEGF with SML and anti-VEGF monotherapy for DME. Outcome measures were best-corrected visual acuity (BCVA), central macular thickness (CMT), and the number of anti-VEGF injections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eight studies including 493 eyes were selected. Four studies were randomized controlled, and the other four were retrospective. Meta-analysis showed that there was no significant difference in BCVA (mean difference [MD] -0.04; 95%CI -0.09 to 0.01 logMAR; P\u2009=\u20090.13;). CMT was thinner in the group of anti-VEGF with SML (MD -11.08; 95%CI -21.04 to -1.12\u00a0\u00b5m; P\u2009=\u20090.03); however, it was due to a single study that weighed higher, and the sensitivity and subcategory analyses did not support the finding. The number of anti-VEGF injections was significantly decreased in the group of anti-VEGF with SML (MD -2.22; 95%CI -3.02 to -1.42; P\u2009&lt;\u20090.0001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Current evidence indicates that adding SML to anti-VEGF therapy could significantly reduce the number of anti-VEGF injections compared to anti-VEGF monotherapy, while achieve similar BCVA and CMT.<\/jats:p>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00417-024-06460-7","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T12:01:39Z","timestamp":1714046499000},"page":"3073-3083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Subthreshold micropulse laser combined with anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"262","author":[{"given":"Hironori","family":"Hosoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-7438","authenticated-orcid":false,"given":"Takashi","family":"Ueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Hirasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Shiraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"6460_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C (2015) Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2:17","journal-title":"Eye Vis (Lond)"},{"key":"6460_CR2","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.survophthal.2022.04.003","volume":"67","author":"GS Sarohia","year":"2022","unstructured":"Sarohia GS, Nanji K, Khan M et al (2022) Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes. Surv Ophthalmol 67:1346\u20131363","journal-title":"Surv Ophthalmol"},{"key":"6460_CR3","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","volume":"103","author":"Early Treatment Diabetic Retinopathy Study research group","year":"1985","unstructured":"Early Treatment Diabetic Retinopathy Study research group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796\u20131806","journal-title":"Arch Ophthalmol"},{"key":"6460_CR4","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ophtha.2008.06.015","volume":"115","author":"Diabetic Retinopathy Clinical Research Network","year":"2008","unstructured":"Diabetic Retinopathy Clinical Research Network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema. Ophthalmology 115:1447\u20131449","journal-title":"Ophthalmology"},{"key":"6460_CR5","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/S0161-6420(97)30061-X","volume":"104","author":"TR Friberg","year":"1997","unstructured":"Friberg TR, Karatza EC (1997) The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. Ophthalmology 104:2030\u20132038","journal-title":"Ophthalmology"},{"key":"6460_CR6","doi-asserted-by":"crossref","unstructured":"Lois N, Campbell C, Waugh N et al; DIAMONDS Study Group (2023) Diabetic macular edema and diode subthreshold micropulse laser: A randomized double-masked noninferiority clinical trial. Ophthalmology 130:14\u201327","DOI":"10.1016\/j.ophtha.2022.08.012"},{"key":"6460_CR7","unstructured":"Higgins J, Thomas J (2023) The Cochrane Handbook for Systematic Reviews of Interventions, version 6.4, 2023. Available at: https:\/\/training.cochrane.org\/handbook\/current. Accessed 29 February 2024"},{"key":"6460_CR8","doi-asserted-by":"publisher","first-page":"i4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:i4898","journal-title":"BMJ"},{"key":"6460_CR9","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"6460_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383\u2013394","journal-title":"J Clin Epidemiol"},{"key":"6460_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"6460_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5301\/ejo.5001000","volume":"28","author":"E Moisseiev","year":"2018","unstructured":"Moisseiev E, Abbassi S, Thinda S et al (2018) Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema. Eur J Ophthalmol 28:68\u201373","journal-title":"Eur J Ophthalmol"},{"key":"6460_CR13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00417-019-04355-6","volume":"257","author":"AM Khattab","year":"2019","unstructured":"Khattab AM, Hagras SM, AbdElhamid A et al (2019) Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 257:1373\u20131380","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6460_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4103\/ijo.IJO_350_19","volume":"68","author":"HS Kanar","year":"2020","unstructured":"Kanar HS, Arsan A, Altun A (2020) Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial. Indian J Ophthalmol 68:145\u2013151","journal-title":"Indian J Ophthalmol"},{"key":"6460_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s10792-019-01280-9","volume":"40","author":"MA Abouhussein","year":"2020","unstructured":"Abouhussein MA, Gomaa AR (2020) Aflibercept plus micropulse laser versus aflibercept monotherapy for diabetic macular edema: 1-year results of a randomized clinical trial. Int Ophthalmol 40:1147\u20131154","journal-title":"Int Ophthalmol"},{"key":"6460_CR16","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s10103-021-03306-0","volume":"36","author":"MG Alt\u0131nel","year":"2021","unstructured":"Alt\u0131nel MG, Acikalin B, Alis MG et al (2021) Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema. Lasers Med Sci 36:1545\u20131553","journal-title":"Lasers Med Sci"},{"key":"6460_CR17","doi-asserted-by":"publisher","first-page":"251584142110408","DOI":"10.1177\/25158414211040887","volume":"13","author":"L El Matri","year":"2021","unstructured":"El Matri L, Chebil A, El Matri K et al (2021) Subthreshold micropulse laser adjuvant to bevacizumab versus bevacizumab monotherapy in treating diabetic macular edema: one- year- follow-up. Ther Adv Ophthalmol 13:25158414211040890","journal-title":"Ther Adv Ophthalmol"},{"key":"6460_CR18","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1007\/s10792-022-02403-5","volume":"42","author":"F B\u0131\u00e7ak","year":"2022","unstructured":"B\u0131\u00e7ak F, Kay\u0131k\u00e7\u0131o\u011flu \u00d6R, Alt\u0131n\u0131\u015f\u0131k M et al (2022) Efficacy of subthreshold micropulse laser combined with ranibizumab in the treatment of diabetic macular edema. Int Ophthalmol 42:3829\u20133836","journal-title":"Int Ophthalmol"},{"key":"6460_CR19","doi-asserted-by":"crossref","unstructured":"Koushan K, Eshtiaghi A, Fung P et al (2022) Treatment of diabetic macular edema with aflibercept and micropulse laser (DAM Study) Clin Ophthalmol 16:1109\u20131115","DOI":"10.2147\/OPTH.S360869"},{"key":"6460_CR20","doi-asserted-by":"publisher","first-page":"e1624","DOI":"10.1111\/aos.15196","volume":"100","author":"MM J\u00f8rgensen","year":"2022","unstructured":"J\u00f8rgensen MM, Vestergaard AH, Blindbaek SL et al (2022) Functional and structural efficacy of a novel combinational therapy of aflibercept and timely focal\/grid photocoagulation in diabetic macular oedema: do clinical study results compare favourably with a standard-of-care treated real-world population? Acta Ophthalmol 100:e1624\u2013e1629","journal-title":"Acta Ophthalmol"},{"key":"6460_CR21","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1097\/IAE.0b013e3181e1ed07","volume":"30","author":"KA Solaiman","year":"2010","unstructured":"Solaiman KA, Diab MM, Abo-Elenin M (2010) Intravitreal bevacizumab and\/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina 30:1638\u20131645","journal-title":"Retina"},{"key":"6460_CR22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/IAE.0b013e318285c99d","volume":"33","author":"KA Solaiman","year":"2013","unstructured":"Solaiman KA, Diab MM, Dabour SA (2013) Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema. Retina 33:1623\u20131629","journal-title":"Retina"},{"key":"6460_CR23","doi-asserted-by":"publisher","first-page":"e113981","DOI":"10.1371\/journal.pone.0113981","volume":"9","author":"R Liegl","year":"2014","unstructured":"Liegl R, Langer J, Seidensticker F et al (2014) Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. PLoS ONE 9:e113981","journal-title":"PLoS ONE"},{"key":"6460_CR24","doi-asserted-by":"crossref","unstructured":"Payne JF, Wykoff CC, Clark WL et al; TREX-DME Study Group (2017) Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREX-DME 1 Year Outcomes. Ophthalmology 124:74\u201381","DOI":"10.1016\/j.ophtha.2016.09.021"},{"key":"6460_CR25","doi-asserted-by":"crossref","unstructured":"Arevalo JF, Lasave AF, Wu L et al; Pan-American Collaborative Retina Study Group (PACORES) (2013) Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months. Retina 33:403\u2013413","DOI":"10.1097\/IAE.0b013e3182695b83"},{"key":"6460_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/08820539909069538","volume":"14","author":"MA Mainster","year":"1999","unstructured":"Mainster MA (1999) Decreasing retinal photocoagulation damage: principles and techniques. Semin Ophthalmol 14:200\u2013209","journal-title":"Semin Ophthalmol"},{"key":"6460_CR27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/bjo.2003.040949","volume":"88","author":"ML Laursen","year":"2004","unstructured":"Laursen ML, Moeller F, Sander B, Sjoelie AK (2004) Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 88:1173\u20131179","journal-title":"Br J Ophthalmol"},{"key":"6460_CR28","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1167\/iovs.10-6828","volume":"52","author":"D Lavinsky","year":"2011","unstructured":"Lavinsky D, Cardillo JA, Melo LA Jr et al (2011) Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 52:4314\u20134323","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6460_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10103-018-2672-9","volume":"34","author":"M Citirik","year":"2019","unstructured":"Citirik M (2019) The impact of central foveal thickness on the efficacy of subthreshold micropulse yellow laser photocoagulation in diabetic macular edema. Lasers Med Sci 34:907\u2013912","journal-title":"Lasers Med Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06460-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06460-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06460-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T03:37:53Z","timestamp":1728358673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06460-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6460"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06460-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"18 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is about systematic review and meta-analysis, and does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors declare no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}